IQVIQVIA Holdings Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Ari Bousbib

Location

North Carolina, USA

Exchange

NYSE

Website

https://iqvia.com

Summary

IQVIA Holdings Inc.

Company Info

CEO

Ari Bousbib

Location

North Carolina, USA

Exchange

NYSE

Website

https://iqvia.com

Summary

IQVIA Holdings Inc.

AI Insights for IQV
5 min read

Quick Summary

IQVIA Holdings Inc. is a healthcare intelligence, data analytics, technology, and clinical research services company serving the global life sciences industry. The company sells cloud-based technology platforms, healthcare data assets, analytics, consulting, clinical trial execution, and outsourced research and development services. Its main customers include biopharmaceutical companies, biotechnology firms, medical device companies, healthcare providers, payers, and other organizations involved in drug development and commercialization. IQVIA operates through major areas such as Technology & Analytics Solutions and Research & Development Solutions, combining proprietary healthcare data with software and services. The company is headquartered in Durham, North Carolina, is led by CEO Ari Bousbib, and operates globally across the Americas, Europe, Africa, and Asia-Pacific.

Strengths

•

IQVIA’s primary strength is its combination of proprietary healthcare data, advanced analytics, technology platforms, and clinical research services.

•

This mix gives the company a differentiated position because it can support customers across commercialization, real-world evidence, clinical development, and strategic decision-making.

•

The company has significant scale, with about 86,000 employees and a global operating footprint across major life sciences markets.

•

IQVIA also benefits from deep relationships with pharmaceutical, biotechnology, medical device, and healthcare customers that often require long-term, specialized support.

•

Its high sentiment rating, strong analyst interest, and reputation as a leading healthcare intelligence provider suggest that many investors still view the company as a high-quality long-term compounder despite recent stock weakness.

Key Risks

•

IQVIA faces the risk that artificial intelligence competitors, technology platforms, or customer-built tools could reduce demand for some analytics or data-related services over time.

•

The company also faces execution risk in clinical research, where trial delays, cancellations, customer budget cuts, regulatory complexity, and operational issues can affect revenue and margins.

•

Integration risk from the Charles River discovery asset acquisition could become material if the acquired sites, technology, or employees do not perform as expected.

•

High debt concerns mentioned by investors could become more important if interest rates remain elevated or if cash flow is weaker than expected.

What to Watch

During the most recent reported period, IQVIA generated operating revenue of about $4.37 billion, gross profit of about $1.44 billion, operating income of about $506 million, and net income of about $258 million.
The company reported basic EPS of $1.54 and diluted EPS of $1.53, while investor attention remained focused on whether profit growth can accelerate in 2026.
A major event was management’s defense of IQVIA’s artificial intelligence strategy after analysts questioned whether new AI tools could threaten its healthcare data and clinical research services.
CEO Ari Bousbib emphasized that IQVIA’s proprietary healthcare data cannot be easily replicated by general AI models.
Another important development was the announced acquisition of selected Charles River Laboratories discovery assets, including in vitro discovery sites and a small-molecule AI platform, which could expand IQVIA’s early-stage R&D capabilities.

Price Drivers

•

IQVIA’s stock price is driven by earnings growth, revenue growth, clinical trial demand, margin trends, backlog conversion, and investor confidence in its long-term healthcare data strategy.

•

The shares recently came under pressure after management forecast 2026 profit below analyst expectations, even though the company beat fourth-quarter expectations.

•

Investor debate is also focused on whether artificial intelligence tools could disrupt parts of IQVIA’s healthcare data, analytics, and clinical research services businesses.

•

Valuation is another important factor, with the company trading at a relatively high price-to-earnings ratio and enterprise-value multiples that require confidence in future growth and margin durability.

•

Broader market trends, healthcare spending, biotechnology funding, interest rates, and pharmaceutical research budgets can all influence demand for IQVIA’s services and the stock’s valuation.

Recent News

•

Recent news has focused heavily on IQVIA’s artificial intelligence strategy and management’s response to analyst concerns about potential disruption.

•

CEO Ari Bousbib defended the company’s position by arguing that IQVIA’s proprietary healthcare data cannot be replicated by general-purpose AI tools.

•

The stock fell sharply after the company issued a 2026 profit forecast below analyst expectations, even though it beat fourth-quarter expectations.

•

IQVIA also announced that it would acquire selected Charles River Laboratories discovery assets, including in vitro drug discovery sites, new approach methodologies capabilities, and a small-molecule AI platform.

•

Analysts still appear constructive overall, with some commentary describing the stock as a strong buy and pointing to meaningful upside if earnings growth and execution improve.

Market Trends

•

The broader market affecting IQVIA is shaped by rising demand for outsourced drug development, growing use of healthcare data, increasing adoption of artificial intelligence, and pressure on pharmaceutical companies to improve R&D productivity.

•

Life sciences companies are using analytics and technology to design better trials, identify patients faster, improve site selection, and make commercialization more efficient.

•

At the same time, customers are scrutinizing costs, and product mix shifts or delayed projects can pressure margins for CROs and healthcare services providers.

•

Regulatory interest in real-world evidence, virtual trials, decentralized trial models, and non-animal research methods may create new opportunities for companies with strong data and operational capabilities.

•

Competitive intensity remains high, and investors are closely watching whether AI becomes a tailwind for established data-rich providers like IQVIA or a disruptive force that compresses pricing and reduces differentiation.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on IQV

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@UndyingValue 1 month ago

OpenAI and Anthropic's push for regulation might just be a cost-saving moat

OpenAI and Anthropic's push for regulation might just be a cost-saving moat

post thumbnail
avatar
@Zalotie 8 months ago

Roundup of today's analyst ratings: Block, PANW, MongoDB, and others

Roundup of today's analyst ratings: Block, PANW, MongoDB, and others

post thumbnail

No more topics to show